Fig. 3.

ARD-61 is much more potent than enzalutamide and ARi-16 in cell growth inhibition in AR+ breast cancer cell lines. (A) Breast cancer cells were pretreated in charcoal-stripped serum (CSS) contained medium for 72 h and then treated with ARD-61, enzalutamide (Enza) or ARi-16 for 7 days with the stimulation of 1 nM R1881. Cell growth was determined by a WST-8 assay. Data are represented as mean ± SEM (n = 3). (B) Breast cancer cells were seeded in 12-well plates and treated with ARD-61, enzalutamide (Enza) or ARi-16 for 10 days in regular medium. Cells were stained with purple crystal.